August 10, 2024Journal of Clinical Oncology

Predictive and pharmacodynamic biomarkers for combination therapy in stage III-IV melanoma: A Simon phase II trial (NCT03999749).

View Full Paper

Ask AI

Bookmark

Authors

TMTeruyuki MizutaniNYU Langone Health TMTomoaki MuramatsuAichi Medical University JHJoanna Handzlik

Discussion

Member takes

Implication

Randomized trial reveals predictive toxicity and response biomarkers in advanced melanoma, suggesting baseline Th17 cells and osteopontin can guide combination immunotherapy.

Key Points

Elevated baseline Th17 cells strongly correlate with severe immune-related adverse events, while triple combination therapy achieved a 57% overall response rate in advanced melanoma.
Severe toxicity affected 22% of patients by week 24, and clinical responders exhibited significant expansions in circulating Treg cells relative to non-responders.
Phase II trial monitoring via multi-parametric flow cytometry evaluated immune subsets and serum proteins in patients receiving nivolumab, ipilimumab, and tocilizumab.
Highlights the utility of baseline Th17 enumeration for risk stratification, while longitudinal osteopontin and Treg tracking may enable real-time monitoring of clinical benefit.

Cite This Study

Mizutani et al. (2024) studied this question.

synapsesocial.com/papers/68e5cc78b6db6435875631af https://doi.org/10.1200/jco.2024.42.23_suppl.222

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals predictive toxicity and response biomarkers in advanced melanoma, suggesting baseline Th17 cells and osteopontin can guide combination immunotherapy.

Predictive and pharmacodynamic biomarkers for combination therapy in stage III-IV melanoma: A Simon phase II trial (NCT03999749).

Discussion

Member takes

Implication

Key Points

Cite This Study

Predictive and pharmacodynamic biomarkers for combination therapy in stage III-IV melanoma: A Simon phase II trial (NCT03999749).

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider